GB201317005D0 - Composition and methods of treatment - Google Patents

Composition and methods of treatment

Info

Publication number
GB201317005D0
GB201317005D0 GBGB1317005.5A GB201317005A GB201317005D0 GB 201317005 D0 GB201317005 D0 GB 201317005D0 GB 201317005 A GB201317005 A GB 201317005A GB 201317005 D0 GB201317005 D0 GB 201317005D0
Authority
GB
United Kingdom
Prior art keywords
treatment
composition
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1317005.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blueberry Therapeutics Ltd
Original Assignee
Blueberry Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49553377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201317005(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Blueberry Therapeutics Ltd filed Critical Blueberry Therapeutics Ltd
Priority to GBGB1317005.5A priority Critical patent/GB201317005D0/en
Publication of GB201317005D0 publication Critical patent/GB201317005D0/en
Priority to GBGB1320723.8A priority patent/GB201320723D0/en
Priority to HUE14781264 priority patent/HUE044589T2/hu
Priority to CN201480052228.3A priority patent/CN105579028B/zh
Priority to EP20209656.6A priority patent/EP3854380A1/en
Priority to EP14781264.8A priority patent/EP3049056B2/en
Priority to HRP20191304TT priority patent/HRP20191304T4/hr
Priority to PCT/GB2014/052911 priority patent/WO2015044669A1/en
Priority to PT14781264T priority patent/PT3049056T/pt
Priority to ES19153995T priority patent/ES2859518T3/es
Priority to RS20190917A priority patent/RS59211B2/sr
Priority to SI201431280T priority patent/SI3049056T2/sl
Priority to ES14781264T priority patent/ES2738662T5/es
Priority to SM20190437T priority patent/SMT201900437T1/it
Priority to JP2016516087A priority patent/JP6581569B2/ja
Priority to PL14781264.8T priority patent/PL3049056T5/pl
Priority to DK14781264.8T priority patent/DK3049056T4/da
Priority to EP19153995.6A priority patent/EP3501498B1/en
Priority to US15/023,602 priority patent/US11185511B2/en
Priority to LTEP14781264.8T priority patent/LT3049056T/lt
Priority to CY20191100783T priority patent/CY1123414T1/el
Priority to JP2019158280A priority patent/JP7028836B2/ja
Priority to US17/512,139 priority patent/US12161764B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1317005.5A 2013-09-25 2013-09-25 Composition and methods of treatment Ceased GB201317005D0 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
GBGB1317005.5A GB201317005D0 (en) 2013-09-25 2013-09-25 Composition and methods of treatment
GBGB1320723.8A GB201320723D0 (en) 2013-09-25 2013-11-25 Composition and methods of treatment
US15/023,602 US11185511B2 (en) 2013-09-25 2014-09-25 Antifungal topical composition and methods of treatment
LTEP14781264.8T LT3049056T (lt) 2013-09-25 2014-09-25 Priešgrybelinė vietinė kompozicija ir gydymo būdai
ES19153995T ES2859518T3 (es) 2013-09-25 2014-09-25 Composición y métodos de tratamiento
SM20190437T SMT201900437T1 (it) 2013-09-25 2014-09-25 Composizione topica antifungina e metodi di trattamento
EP20209656.6A EP3854380A1 (en) 2013-09-25 2014-09-25 Composition and methods of treatment
EP14781264.8A EP3049056B2 (en) 2013-09-25 2014-09-25 Antifungal topical composition and methods of treatment
HRP20191304TT HRP20191304T4 (hr) 2013-09-25 2014-09-25 Antigljivični pripravak i postupci liječenja
PCT/GB2014/052911 WO2015044669A1 (en) 2013-09-25 2014-09-25 Antifungal topical composition and methods of treatment
PT14781264T PT3049056T (pt) 2013-09-25 2014-09-25 Composição tópica antifúngica e métodos de tratamento
HUE14781264 HUE044589T2 (hu) 2013-09-25 2014-09-25 Gombaellenes helyi készítmény és kezelési eljárások
RS20190917A RS59211B2 (sr) 2013-09-25 2014-09-25 Antifungalni topikalni sastav i postupci tretmana
SI201431280T SI3049056T2 (sl) 2013-09-25 2014-09-25 Protiglivični topikalni sestavki in postopki zdravljenja
ES14781264T ES2738662T5 (es) 2013-09-25 2014-09-25 Composición tópica antifúngica y métodos de tratamiento
CN201480052228.3A CN105579028B (zh) 2013-09-25 2014-09-25 抗真菌局部组合物及治疗方法
JP2016516087A JP6581569B2 (ja) 2013-09-25 2014-09-25 抗真菌局所組成物および処置の方法
PL14781264.8T PL3049056T5 (pl) 2013-09-25 2014-09-25 Przeciwgrzybicza kompozycja do stosowania miejscowego i sposoby leczenia
DK14781264.8T DK3049056T4 (da) 2013-09-25 2014-09-25 Topisk antisvampesammensætning og fremgangsmåder til behandling
EP19153995.6A EP3501498B1 (en) 2013-09-25 2014-09-25 Composition and methods of treatment
CY20191100783T CY1123414T1 (el) 2013-09-25 2019-07-24 Antiμυκητιασικη τοπικη συνθεση και μεθοδοι θεραπειας
JP2019158280A JP7028836B2 (ja) 2013-09-25 2019-08-30 抗真菌局所組成物および処置の方法
US17/512,139 US12161764B2 (en) 2013-09-25 2021-10-27 Composition and methods of treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1317005.5A GB201317005D0 (en) 2013-09-25 2013-09-25 Composition and methods of treatment

Publications (1)

Publication Number Publication Date
GB201317005D0 true GB201317005D0 (en) 2013-11-06

Family

ID=49553377

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1317005.5A Ceased GB201317005D0 (en) 2013-09-25 2013-09-25 Composition and methods of treatment
GBGB1320723.8A Ceased GB201320723D0 (en) 2013-09-25 2013-11-25 Composition and methods of treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
GBGB1320723.8A Ceased GB201320723D0 (en) 2013-09-25 2013-11-25 Composition and methods of treatment

Country Status (17)

Country Link
US (2) US11185511B2 (enExample)
EP (3) EP3854380A1 (enExample)
JP (2) JP6581569B2 (enExample)
CN (1) CN105579028B (enExample)
CY (1) CY1123414T1 (enExample)
DK (1) DK3049056T4 (enExample)
ES (2) ES2738662T5 (enExample)
GB (2) GB201317005D0 (enExample)
HR (1) HRP20191304T4 (enExample)
HU (1) HUE044589T2 (enExample)
LT (1) LT3049056T (enExample)
PL (1) PL3049056T5 (enExample)
PT (1) PT3049056T (enExample)
RS (1) RS59211B2 (enExample)
SI (1) SI3049056T2 (enExample)
SM (1) SMT201900437T1 (enExample)
WO (1) WO2015044669A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317005D0 (en) * 2013-09-25 2013-11-06 Blueberry Therapeutics Ltd Composition and methods of treatment
US12290599B2 (en) 2015-06-19 2025-05-06 Global Health Solutions Llc Oil-based wound care compositions and methods
US11110071B2 (en) * 2015-06-19 2021-09-07 Global Health Solutions Llc Petrolatum-based PHMB compositions and methods of treatment for onychomycosis
GB201511799D0 (en) 2015-07-06 2015-08-19 Blueberry Therapeutics Ltd Composition and methods of treatment
EP3393518B1 (en) * 2015-12-23 2024-10-30 Aarhus Universitet Antifungal agent
US20200093956A1 (en) * 2016-03-24 2020-03-26 Locate Therapeutics Limited Scaffolding material, methods and uses
GB201605127D0 (en) 2016-03-25 2016-05-11 Blueberry Therapeutics Ltd Composition and methods of treatment
JP6310977B2 (ja) * 2016-09-07 2018-04-11 株式会社日本総合研究所 爪用シール及びシールシート
WO2018162271A1 (en) 2017-03-05 2018-09-13 Rita Dobmeyer Nanoparticles for the treatment of macular degeneration
GB201710491D0 (en) * 2017-06-30 2017-08-16 Blueberry Therapeutics Ltd Composition and methods of treatment
KR102060138B1 (ko) * 2018-05-30 2019-12-27 연세대학교 산학협력단 안구용 마이크로니들 주사의 제조방법
GB201810925D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and methods of treatment
GB201810923D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and method of treatment
US12115139B2 (en) * 2018-08-15 2024-10-15 Todd Alan Weinfield Treatment methods and processes for an infected nail
EP3911306B1 (en) * 2019-01-16 2023-12-20 Global Health Solutions, LLC Petrolatum-based phmb compositions and methods of treatment for onychomycosis
GB201908229D0 (en) * 2019-06-10 2019-07-24 Univ College Cork National Univ Of Ireland Microneedles and methods for the manufacture thereof
CN110898075B (zh) * 2019-12-27 2021-08-03 温海 聚六亚甲基双胍在制备抑制和/或杀灭犬小孢子菌的药物中的应用
CN111067897A (zh) * 2020-01-20 2020-04-28 中山大学 一种抗真菌的组合物及其应用
IL295800A (en) * 2020-02-26 2022-10-01 Biosergen As Pharmaceutical compositions of a therapeutic polyene macrolide and methods of their use
CN111588689B (zh) * 2020-06-20 2023-08-11 温州医科大学 一种角膜微创可溶性微针贴片及其制备方法与应用
CN112168845A (zh) * 2020-11-13 2021-01-05 郑虹 一种用于治疗手足癣的药物软膏及其制备方法
JP2022118704A (ja) * 2021-02-02 2022-08-15 国立大学法人 鹿児島大学 ナノ粒子組成物、抗菌抗かび抗ウイルス剤、抗菌抗かび抗ウイルス塗料、抗菌抗かび抗ウイルス剤調製キット及びナノ粒子組成物の製造方法
DE102021118997A1 (de) * 2021-07-22 2023-01-26 Lts Lohmann Therapie-Systeme Ag. Mikronadelarray mit Antiseptika
CN113567217A (zh) * 2021-07-27 2021-10-29 肖波 一种妇科荧光染色液
WO2023154464A1 (en) * 2022-02-11 2023-08-17 Fairleigh Dickinson University Locally administered compositions and methods of use thereof
KR102597564B1 (ko) * 2023-03-03 2023-11-03 장병모 조갑 및 피부 백선의 예방 또는 치료용 약학적 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761886B1 (fr) * 1997-04-14 2000-05-05 Virbac Sa Compositions contenant au moins un polymere cationique et au moins une molecule active contenue dans au moins un vecteur micro ou nanoparticulaire, et leur utilisation pour le traitement de surfaces vivantes ou inertes
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
EP1635770B1 (en) * 2003-03-21 2009-05-27 Nexmed Holdings, Inc. Antifungal nail coat and method of use
CN102309473A (zh) * 2003-07-17 2012-01-11 纽约市哥伦比亚大学托管会 含有季铵化合物及精油和/或精油成分的协同组合的抗微生物组合物
US20050238672A1 (en) * 2004-04-27 2005-10-27 Nimni Marcel E Antifungal drug delivery
US20050249818A1 (en) 2004-05-03 2005-11-10 Sawan Samuel P Polycationic antimicrobial therapeutic
WO2006138719A2 (en) * 2005-06-17 2006-12-28 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
ATE477833T1 (de) 2005-06-27 2010-09-15 3M Innovative Properties Co Mikronadelkartuschenanordnung
CA2614927A1 (en) * 2005-07-25 2007-02-01 Nanotechnology Victoria Pty Ltd Microarray device
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
AR062334A1 (es) 2006-08-11 2008-10-29 Panacea Biotec Ltd Particulas para suministrar ingredientes activos, proceso para hacerlas y composiciones de las mismas
AU2007333528B2 (en) * 2006-10-05 2013-10-17 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
WO2010011354A2 (en) * 2008-07-25 2010-01-28 Innovation Biomedical Devices, Inc. Enchanced trans-keratin drug delivery
CN101724284B (zh) * 2008-10-31 2012-06-27 中国石油化工股份有限公司 一种抗菌热塑性塑料组合物及其制备方法
JP5408592B2 (ja) 2010-03-19 2014-02-05 コスメディ製薬株式会社 マイクロニードルの迅速溶解法
JP2012235899A (ja) 2011-05-12 2012-12-06 Bioserentack Co Ltd 大量の目的物質を皮膚内へデリバリーするためのマイクロニードル・アレイ・チップ
JP6336902B2 (ja) * 2011-06-22 2018-06-06 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド コンジュゲートベースの抗真菌性および抗菌性プロドラッグ
GB201117538D0 (en) 2011-10-11 2011-11-23 Royal Veterinary College The Methods
EP2664327A1 (en) * 2012-05-14 2013-11-20 Almirall S.A. Topical pharmaceutical compositions comprising terbinafide and urea
GB201317005D0 (en) * 2013-09-25 2013-11-06 Blueberry Therapeutics Ltd Composition and methods of treatment

Also Published As

Publication number Publication date
EP3501498A1 (en) 2019-06-26
WO2015044669A1 (en) 2015-04-02
ES2738662T3 (es) 2020-01-24
PL3049056T5 (pl) 2022-09-12
LT3049056T (lt) 2019-08-26
CN105579028B (zh) 2020-03-20
EP3049056B2 (en) 2022-06-01
SI3049056T2 (sl) 2022-08-31
SI3049056T1 (sl) 2019-11-29
JP2019218393A (ja) 2019-12-26
JP6581569B2 (ja) 2019-09-25
US12161764B2 (en) 2024-12-10
EP3049056B1 (en) 2019-04-24
EP3049056A1 (en) 2016-08-03
CN105579028A (zh) 2016-05-11
DK3049056T3 (da) 2019-07-29
US11185511B2 (en) 2021-11-30
RS59211B1 (sr) 2019-10-31
EP3854380A1 (en) 2021-07-28
HRP20191304T4 (hr) 2022-07-22
HRP20191304T1 (hr) 2019-10-18
GB201320723D0 (en) 2014-01-08
PT3049056T (pt) 2019-07-25
JP2016536271A (ja) 2016-11-24
HUE044589T2 (hu) 2019-11-28
ES2859518T3 (es) 2021-10-04
ES2738662T5 (es) 2022-09-21
JP7028836B2 (ja) 2022-03-02
US20160206567A1 (en) 2016-07-21
CY1123414T1 (el) 2022-03-24
US20220133640A1 (en) 2022-05-05
RS59211B2 (sr) 2022-07-29
SMT201900437T1 (it) 2019-09-09
DK3049056T4 (da) 2022-08-01
PL3049056T3 (pl) 2019-10-31
EP3501498B1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
GB201320723D0 (en) Composition and methods of treatment
IL286759A (en) Therapeutic methods and preparations
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
IL239453B (en) Preparations and methods for treating cancer using bacteria
SG11201507135XA (en) Methods of maintaining and improving muscle function
PT3021839T (pt) Composições para o tratamento da fibrose
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
SG11201507978XA (en) Vaccine composition and method of use
SG11201510300RA (en) Compositions and methods for treating skin
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
IL241096B (en) Treatment methods
ZA201509360B (en) Compositions and methods for treatment of stroke
GB201518035D0 (en) Prebiotic composition and method of its use
SI2992094T1 (sl) Sestavki in postopki za zdravljenje diabetesa tipa 1
GB201310349D0 (en) Composition and method of use thereof
GB201301928D0 (en) Composition and method of use thereof
GB201319255D0 (en) Therapeutic compositions and methods
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)